Impact of elexacaftor/tezacaftor/ivacaftor on utilization of routine therapies in cystic fibrosis: Danish nationwide register study
Two years after ETI initiation, reductions in the use of several routine therapies were observed in a national cohort of pwCF, with the largest declines in airway medications and antibiotics. These findings highlight ETI's real-world impact beyond conventional clinical metrics.
Authors
- Søren Jensen‐Fangel
- Espen Jimenez‐Solem (ORCID: https://orcid.org/0000-0002-3777-147X)
- Hans Kristian Pedersen (ORCID: https://orcid.org/0009-0005-7959-1548)
- Camilla Bjørn Jensen (ORCID: https://orcid.org/0000-0002-8224-4601)
- Marianne Skov (ORCID: https://orcid.org/0000-0002-7131-8548)
- Janne Petersen (ORCID: https://orcid.org/0000-0001-7323-2548)
- Hanne Vebert Olesen (ORCID: https://orcid.org/0000-0003-4000-210X)
- Joanna Wang (ORCID: https://orcid.org/0000-0003-1723-1342)
- Tacjana Pressler
Institutions
- Frederiksberg Hospital (DK)
- Aarhus University Hospital (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
Publication Details
- Journal
- Journal of Cystic Fibrosis
- Published
- 2024-11-24
- DOI
- https://doi.org/10.1016/j.jcf.2024.11.004
- Citations
- 8
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 3.35
Funders
- Vertex Pharmaceuticals